Phase 1 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Men, or women who have gone through menopause or had a surgical procedure that means they can no longer become pregnant, aged between 65 and 80 years old
- People whose thinking and memory are currently normal (not showing signs of cognitive impairment), based on specific memory and thinking tests (confirm with trial site for exact test score requirements)
- People whose blood test results show early signs of Alzheimer's-related protein buildup in the brain, even though no symptoms are present yet, as measured by a specific test called PrecivityAD2™
- People with good enough vision and hearing to take part in all study activities
- People whose regular medications have been at a stable dose (if they take any), and who are willing to give written agreement to participate
Who may not be able to join:
- People whose brain MRI scan shows certain abnormalities, such as signs of past strokes, more than five small bleeds in the brain, or other significant findings
- People who cannot have an MRI scan for any reason, such as having a pacemaker, certain metal implants in the body, or severe fear of enclosed spaces
- People who have had a serious illness or been hospitalised in the four weeks before joining the trial
- People with significant heart, hormonal, blood, immune system, or neurological conditions
- People with insulin-dependent diabetes, significant heart rhythm problems, or a history of seizures
- People who have scored at a certain level or above on a suicide risk assessment questionnaire (confirm with trial site for details)
- People who have received a treatment targeting tau or amyloid-beta proteins (two proteins linked to Alzheimer's disease) within the past year
- People taking medications that suppress the immune system or prevent blood clotting, if those medications could affect safety in the trial
- People with significant abnormal results on routine blood tests, or people who test positive for HIV, hepatitis B, or hepatitis C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Michael Agadjanyan, PhD, Institute MM
Phone: 7145963981
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.